1399119-69-7

Upstream product

• 118-92-3 anthranilic acid 
• 86-96-4 1,2,3,4-tetrahydro-quinazoline-2,4-dione 
• 1399119-66-4 5-((2,4-dioxo-3,4-dihydroquinazoline-1(2H)-yl)methyl)-2-fluorobenzoic acid 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 1401681-62-6 5-((2,4-dioxo-3,4-dihydroquinazolin-1(2Η)-yl)methyl)-2-fluorobenzoic acid methyl ester 
• 616890-29-0 N-tert-butyl-N′-(methoxycarbonyl)-2-aminobenzamide 
• 709-45-5 2-fluoro-5-bromomethyl benzoic acid methyl ester 
• 2967-93-3 2-fluoro-5-methyl benzoic acid methyl ester 
• 1209-77-4 3-tert-butyl-1,2,3,4-tetrahydroquinazoline-2,4-dione 
• 118-48-9 isatoic anhydride 
• 321-12-0 2-fluoro-5-methyl-benzoic acid 

Downstream Products

• 1399119-49-3 C₂₆H₂₂FN₅O₄ 
• 1399119-60-8 C₂₃H₂₃FN₄O₅ 

Relevant academic research and scientific papers

Quinazolinone PARP-1 inhibitors, medicinal composition containing inhibitors, and antitumor use of inhibitors

The invention discloses quinazolinyl-2,4(1H,3H)-dione PARP-1 inhibitors, and a preparation method, a medicinal composition and a use thereof. The invention concretely relates to quinazolinyl-2,4(1H,3H)-dione derivatives represented by general formula I, a medicinal salt and a preparation method thereof, a composition containing one or more of the compounds, and a use of the compounds in the preparation of tumor prevention and/or treatment medicines.

QUINAZOLINEDIONES AND THEIR USE

The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts or prodrugs thereof, which inhibit the poly(ADP-ribose) polymerases (PARP) and therefore are useful for treating diseases, disorders, and conditions related to PARP. The present invention also discloses pharmaceutical compositions comprising a compound of formula (I), and methods of using such compounds to inhibit PARP enzymes, and to treat diseases, disorders, and conditions related to PARP.